5.10p
-2.86%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About hVIVO
Its shares trade on LSE under the ticker HVO.L. It has been listed since 14 December 2012. In the fiscal year to 31 December 2025, it reported revenue of £46.8m and a net loss of £6.0m. At that date it held total assets of £71.8m and shareholders' equity of £38.2m.
Open Orphan Plc provides pharmaceutical development services. The firm is also engaged in building an orphan drug consulting services platform that helps pharma companies commercialize their products in Europe. The firm consists of four elements: a European clinical research organization and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians, and a Health Data Platform. The firm provides fragmented orphan drug services. The firm acquires and consolidates series of orphan drug services companies. The company also provides digital data platforms to support companies in research & development and commercialization.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 14 Dec 2012
- Employees
- 132
- Website
- vennlifesciences.com ↗
Leadership
Pay as last reported
- Mr. Shaun ChiltonNon-Executive Chairman of the Board
- Dr. Yamin Mohammed KhanChief Executive Officer, Executive Director, since 2021£697,000
- Mr. Stephen PinkertonChief Financial Officer, Executive Director, since 2022£349,000
- Prof. Brendan BuckleyNon-Executive Director£45,000
- Dr. Elaine SullivanSenior Independent Non-Executive Director£45,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 82
- Social
- 76
- Governance
- 20
- Direct emissions (scope 1)
- 14.9 t
- Energy emissions (scope 2)
- 162.8 t
- Value chain emissions (scope 3)
- 14.7 t
- Women in the workforce
- 61%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Reputation: Open Orphan PLC has built a strong reputation in the pharmaceutical and biotech sectors, positioning itself as a reliable and trusted partner.
- Expertise in Rare Diseases: The company specializes in the development of treatments for rare diseases, leveraging its in-house expertise and scientific knowledge in this niche market.
- Comprehensive Service Portfolio: Open Orphan PLC offers a wide range of services, including clinical research, laboratory testing, and consultancy, providing clients with integrated solutions.
Weaknesses
- Limited Global Presence: Open Orphan PLC's operations are primarily focused on specific regions, which may limit its ability to tap into global markets and reach a wider client base.
- Dependency on Key Clients: The company relies heavily on a few key clients for a significant portion of its revenue, making it susceptible to potential client losses and revenue fluctuations.
- Higher Costs: The nature of rare disease research and development often requires extensive resources and specialized facilities, resulting in higher operational costs for Open Orphan PLC.
Opportunities
- Growing Demand for Rare Disease Treatments: The increasing prevalence of rare diseases and the need for effective treatments presents an opportunity for Open Orphan PLC to expand its client base and grow its revenue.
- Strategic Partnerships: Collaborating with pharmaceutical companies and research organizations can provide Open Orphan PLC with access to additional resources, expertise, and a broader network for business development.
- Expansion into Emerging Markets: Exploring expansion into untapped markets with high growth potential, particularly in regions where rare disease research and treatments are gaining traction, can help Open Orphan PLC diversify its business and increase its market reach.
Threats
- Strong Competition: Open Orphan PLC operates in a highly competitive industry, facing competition from larger and well-established contract research organizations, which may pose a challenge to its market share and growth prospects.
- Regulatory Uncertainties: The pharmaceutical and biotech sectors are subject to extensive regulations and compliance requirements. Changes in regulatory frameworks or delays in approvals can impact Open Orphan PLC's operations and profitability.
- Economic Instability: Economic downturns or fluctuations in the broader economy can adversely affect the pharmaceutical industry, potentially leading to budget cuts in research and development, which may indirectly impact Open Orphan PLC's business.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.